Thermo Fisher Partners With HealthVerity To Boost Data-Driven Clinical Research
Thermo Fisher Scientific partners with HealthVerity to access 270M patient records, enhancing AI-driven clinical trials, site selection, and real-world evidence generation.
Breaking News
Apr 14, 2026
Vaibhavi M.
Thermo Fisher Scientific has announced a strategic data collaboration with HealthVerity to advance data-driven clinical development and evidence generation for biopharma companies. The partnership will provide Thermo Fisher’s PPD clinical research business with enterprise-level access to HealthVerity’s TaXOnomy claims dataset, covering more than 270 million de-identified patient records across the U.S. healthcare system.
This extensive dataset will enable deeper insights into disease prevalence, treatment patterns, and healthcare provider activity. By leveraging these insights, Thermo Fisher aims to strengthen its AI- and data-driven capabilities across key areas such as trial feasibility, site selection, patient recruitment, and real-world evidence generation, ultimately improving the efficiency and precision of clinical trials.
“This collaboration advances our ability to integrate high-quality, linked healthcare data into clinical development,” said Krishna Cheriath, vice president, head of clinical research digital and AI, biopharma services, Thermo Fisher Scientific. “By utilizing one of the largest integrated healthcare data ecosystems with our AI-enabled analytics, we can generate robust real-world evidence to support our customers across the clinical and post-approval continuum.”
The collaboration also unlocks access to over 70 curated data sources, including electronic medical records, lab results, and specialty datasets. This integrated and longitudinal data approach is expected to enhance trial optimization strategies, accelerate study start-up timelines, and support more informed decision-making throughout the clinical development process.
“We’re proud to support Thermo Fisher’s PPD clinical research business in advancing data-driven clinical development,” said Joseph Satili, chief commercial officer, HealthVerity. “With enterprise access to robust real-world insights, teams can move faster and with greater confidence, from feasibility through evidence generation, improving how studies are designed and executed.”
Additionally, the partnership will expand Thermo Fisher’s real-world evidence and health economics and outcomes research (HEOR) capabilities through its PPD CorEvitas Clinical Registries and PPD Evidera solutions. With a focus on maintaining strong data privacy and governance standards, the collaboration reinforces the company’s commitment to digital innovation and improving patient outcomes through smarter clinical research.
Also Read :
